Synthesis and anticancer activity of novel 2-amino-4-(4-phenylpiperazino)- 1,3,5-triazine derivatives

Acta Poloniae Pharmaceutica - Drug Research

Volumn 61, Issue 6, 2004, Pages 461-466

  Pomarnacka, Elzbieta ^a   Bednarski, Patrick ^b   Grunert, Renate ^b   Reszka, Przemysław ^b  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

2 Amino 4 (4 phenylpiperazino) 1,3,5 triazine derivatives; Anticancer activity; Synthesis

Indexed keywords

2 [2 AMINO 4 [4 (2 CHLOROPHENYL)PIPERAZINO] 1,3,5 TRIAZIN 6 YL] 3 (4 NITROPHENYL)ACRYLONITRILE; 2 AMINO 4 (4 PHENYLPIPERAZINO) 1,3,5 TRIAZINE; CYTOTOXIC AGENT; PIPERAZINE DERIVATIVE; TRIAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; DRUG CYTOTOXICITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; INFRARED SPECTROSCOPY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INDICATORS AND REAGENTS; PIPERAZINES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; SPECTROPHOTOMETRY, INFRARED; TRIAZINES;

EID: 13244277732     PISSN: 00016837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Negwer M.: Organic-Chemical Drugs and Their Synonyms, Wiley-VCH Verlag GmbH-Weinheim, 2001.
2. Jarman M., Coleg H.M., Judson I.R., Thornton T.J., Wilman D.E.V.: J. Med. Chem. 36, 4195 (1993).
3. Soudon J., Berlion M., Lucas C. Haddad P., Calvo F.: Cancer Chemother. Pharmacol. 36, 195, (1995).
4. Tassin J.P., Dubois J., Hanocq M., Atassi G.: Talanta 42, 747 (1995).
5. Ono M., Kawahara N., Goto D. Wakabayashi Y., UshiroS.: Cancer Res. 56, 1512 (1996).
6. Brzozowski Z., Saczewski F., Gdaniec M.: Eur. J. Med. Chem. 35, 1053 (2000).
7. Brzozowski Z., Saczewski F.: Eur. J. Med. Chem. 37, 709 (2002).
8. Das P. C.: Indian J. Chem. 6, 691 (1968).
9. Bernhardt G., Reile H., Birnböck H., Spruß T., Schönenberger H.: J. Cancer Res. Clin. Oncol. 118, 35 (1992).
10. Brzozowski Z., Kozakiewicz I., Angielski S.: Acta Polon. Pharm. 36, 401 (1979).
11. Molecular modeling studies were performed at ab initio level using the Hartree-Fock method with 6-31G** basis set and non-local density functional modules as implemented into TITAN program Version 1,0,5 (2000), Wavefunction Inc. Schrödinger Inc.